• 1
    Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:17331745.
  • 2
    Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006; 12:914.
  • 3
    Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21:17691775.
  • 4
    Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults; in Nicholson KG, Webster RG, Hay AJ (eds): Textbook of influenza. Oxford: Blackwell Science, 1998; 358372.
  • 5
    De Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in elderly. J Med Virol 2000; 61:9499.
  • 6
    Doherty PC, Turner SJ, Webby RG, Tomas PG. Influenza and the challenge for immunology. Nat Immunol 2006; 7:449455.
  • 7
    Doherty PC, Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008; 118:32733275.
  • 8
    Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986; 58:417420.
  • 9
    Budimir N, Huckriede A, Meijerhof T et al. Induction of heterosubtypic crossprotection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS ONE 2012; 7:e30898.
  • 10
    Mohanan D, Slutter B, Henriksen-Lacev M et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010; 147:342349.
  • 11
    Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L. The mode of presentation and route of administration are critical for the induction of immune response to p53 and antitumor immunity. Vaccine 1998; 16:208215.
  • 12
    Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008; 38:114126.
  • 13
    Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan A. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. Vaccine 2010; 25:82808287.
  • 14
    Liu H, Bungener L, ter Veer W, Coller BA, Wilschut J, Huckriede A. Preclinical evaluation of the saponin derivative GPI-100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 2011; 11:20372043.
  • 15
    De Haan A, Renegar KB, Small PA, Wilschut J. Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen. Vaccine 1995; 13:613616.
  • 16
    Decrausaz L, Domingos-Pereira S, Duc M et al. Parenteral is more efficient than mucosal immunization to induce regression of human papilloma virus-associated genital tumors. Int J Cancer 2011; 129:762772.
  • 17
    Wraith DC, Vessey E, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 1987; 68:433440.
  • 18
    Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and a challenge. Nat Rev Immunol 2006; 6:L148L158.
  • 19
    Slutter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target 2008; 16:117.
  • 20
    Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998; 188:409414.
  • 21
    Lee HK, Zamora M, Linehan MM et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J Exp Med 2009; 206:259270.
  • 22
    Masson F, Mount AM, Wilson NS, Belz GT. Dendritic cells: driving the differentiation program of T cells in viral infections. Immunol Cell Biol 2008; 86:3342.
  • 23
    Mestecky J, Moldoveanu Z, Elson CO. Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine 2005; 23:18001803.
  • 24
    Waldo FB, van den Wall Bake AW, Mestecky J, Husby S. Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol 1994; 72:3034.
  • 25
    Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol 2007; 179:56335638.
  • 26
    Kreijtz JHCM, Bodewes R, van Amerongen G et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic strain in mice. Vaccine 2007; 25:612620.
  • 27
    Bodewes R, Kreijtz JHCM, Geelhoed-Mieras MM et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 2011; 85:26952702.
  • 28
    Weinfurter JT, Brunner K, Capuano SV 3rd et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1n1 influenza virus in non-human primates. PLoS Pathog 2011; 7:e1002381.
  • 29
    Nguyen HH, Moldoveanu Z, Novak MJ et al. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 1999; 254:5060.
  • 30
    Hillaire ML, van Trierum SE, Kreijtz JH et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific CD8+ T cells. J Gen Virol 2011; 92:23392349.
  • 31
    Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003; 21:32123218.
  • 32
    Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001; 14:430445.
  • 33
    Price GE, Soboleski MR, Lo CY et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 2010; 5:e13162.
  • 34
    Alsharifi M, Furuya Y, Bowden TR et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS ONE 2009; 4:e5336.
  • 35
    Furuya Y, Chan J, Wan E et al. Gamma-Irradiated Influenza Virus Uniquely Induces IFN-I Mediated Lymphocyte Activation Independent of the TLR7/MyD88 Pathway. PLoS ONE 2011; 6:e25765.
  • 36
    Gilker JC, Pavilanis V, Ghys R. Multiplicity reactivation in gamma irradiated influenza viruses. Nature 1967; 214:12351237.
  • 37
    Brooke CB, Ince WL, Wrammert J et al. Most influenza A virions fail to express at least one essential viral protein. J Virol 2013; 87:31553162.
  • 38
    Bodewes R, Kreijtz JH, Hillaire ML et al. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T cell responses in mice. J Gen Virol 2010; 91:17431753.
  • 39
    Asahi-Ozaki Y, Yoshikawa T, Iwakura Y et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 2004; 74:325335.
  • 40
    Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008; 82:13501359.
  • 41
    Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001; 75:51415150.